leisure time -WSS

leisure time

author：focus 2025-08-11 08:00:16 - browse：7

Liver illustration — Hyacinth Empinado/STAT

SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, an increasingly prevalent condition that can lead to serious liver damage.

There are no approved medications for the disease, but among available diabetes drugs, the ADA singled out GLP-1 treatments as an option doctors could consider, according to recommendations published during the annual ADA conference.

GLP-1 treatments, such as Ozempic and Mounjaro, are a class of drugs that have grown widely popular for their efficacy not only in lowering blood sugar, but also cutting weight. Drugmakers have started to study them in liver disease, and while some trials have shown they may offer some benefits, they haven’t yet been shown to improve harmful liver scarring.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Why health care costs have stayed mostly flat since 2010

entertainment

WSS

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Violet CEO on training clinicians to promote more inclusive care

Reports of telehealth's death have been greatly exaggerated

Carvykti CAR

Carvykti CAR

Carvykti CAR

explore

leisure time

focus

Alkermes shareholders re

As a primary care physician, here's how I hope to partner with AI

Hollywood unions extend contract negotiations for actors

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Medicare proposal to cover medical devices draws a mixed reaction

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

New air purifier tech could be key to improving indoor air quality

CRISPR gene editing developments we’re watching in 2024

Moonlake's readout produced a cash windfall. Risks remain

Albert Bourla of Pfizer: worst biopharma CEO of 2023

explore

Carvykti CAR

FDA poised to publish guidelines for clinical trial diversity

ASCO eve: Let’s set the table for this year's meeting

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

What STAT readers think about the FDA and patient advocacy

Medicare drug price negotiation hasn't dried up venture capital

entertainment

knowledge

entertainment

leisure time